Avoiding pitfalls in the pursuit of a COVID-19 vaccine

Positive RT-PCR test results in patients recovered from COVID-19

Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., & Xu, H. (2020) · JAMA · doi:10.1001/jama.2020.2783 · Cited by 1,251

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477

Antibody-Dependent Enhancement of Virus Infection and Disease

Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Acosta, P. L., Caballero, M. T., & Polack, F. P. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00609-15 · Cited by 259

Immune Enhancement of Viral Infection

Halstead, S. B. (2015) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000406537 · Cited by 210

Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)Preprint

Ricke, D. O., & Malone, R. W. (2020) · SSRN Electronic Journal · doi:10.20944/preprints202003.0138.v1 · Cited by 48

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

Adaptive immunity to SARS-CoV-2 and COVID-19

Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860

Estimating the burden of SARS-CoV-2 in France

Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038

Immune response, inflammation, and the clinical spectrum of COVID-19

García, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01441 · Cited by 739

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706

COVID-19 vaccine development and a potential nanomaterial path forward

Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 660

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 476

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

Călina, D. C., Docea, A. O., Petrakis, D., Egorov, A. M., Ishmukhametov, A. A., Gabibov, A., Штильман, М. И., Kostoff, R. N., Carvalho, F. D., Vinceti, M., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4596 · Cited by 319

Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray

de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Felgner, J. H., Obiero, J. M., Norris, P. J., Stone, M., Simmons, G., Bagri, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20095-2 · Cited by 201

SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target

Xia, B., Shen, X.-R., He, Y., Pan, X., Liu, F., Wang, Y., Yang, F., Fang, S., Wu, Y. L., Duan, Z., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00519-4 · Cited by 197

T Cell Responses to SARS-CoV-2

Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 191

Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19

Huang, J., Song, W., Huang, H., & Sun, Q. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041131 · Cited by 165

COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics

Amawi, H. A., Deiab, G. A., Aljabali, A. A. A., Dua, K., & Tambuwala, M. M. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0035 · Cited by 155

Taking the pulse of COVID-19: a spatiotemporal perspective

Yang, C. P., Sha, D., Liu, Q., Li, Y., Lan, H., Guan, W. W., Hu, T., Li, Z., Zhang, Z., Thompson, J. H., et al. (2020) · International Journal of Digital Earth · doi:10.1080/17538947.2020.1809723 · Cited by 114

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J., & Haynes, B. F. (2020) · Cell · doi:10.1016/j.cell.2020.05.041 · Cited by 102

Nanocarrier vaccines for SARS-CoV-2

Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 100

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

DiPiazza, A. T., Leist, S. R., Abiona, O. M., Moliva, J. I., Werner, A. P., Minai, M., Nagata, B. M., Bock, K. W., Phung, E., Schäfer, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.018 · Cited by 92

COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

Singh, R., Kang, A., Luo, X., Jeyanathan, M., Gillgrass, A. E., Afkhami, S., & Xing, Z. (2021) · The FASEB Journal · doi:10.1096/fj.202002662r · Cited by 101

COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!

Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.06.003 · Cited by 92

Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19

Karthik, K., Senthilkumar, T. M. A., Udhayavel, S., & Raj, G. D. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1796425 · Cited by 87

COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

Moore, J. P., & Klasse, P. J. (2020) · Journal of Virology · doi:10.1128/jvi.01083-20 · Cited by 87

Evidence for Strong Mutation Bias toward, and Selection against, U Content in SARS-CoV-2: Implications for Vaccine Design

Rice, A. M., Castillo-Morales, A., Ho, A. T., Mordstein, C., Mühlhausen, S., Watson, S., Cano, L., Young, B., Kudla, G., & Hurst, L. D. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa188 · Cited by 85

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization

Klasse, P. J., & Moore, J. P. (2020) · eLife · doi:10.7554/elife.57877 · Cited by 79

Current Status of COVID‐19 (Pre)Clinical Vaccine Development

Ye, T., Zhong, Z., García‐Sastre, A., Schotsaert, M., & Geest, B. G. D. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008319 · Cited by 73

Nanomaterial Based Biosensors for Detection of Viruses Including SARS-CoV-2: A Review

Bisht, A., Mishra, A., Bisht, H. S., & Tripathi, R. M. (2021) · Journal of Analysis and Testing · doi:10.1007/s41664-021-00200-0 · Cited by 73

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

Călina, D. C., Sarkar, C. K., Arsene, A. L., Salehi, B., Docea, A. O., Mondal, M., Islam, M. T., Zali, A., & Sharifi‐Rad, J. (2020) · Immunologic Research · doi:10.1007/s12026-020-09154-4 · Cited by 69

Advancements in protein nanoparticle vaccine platforms to combat infectious disease

Butkovich, N., Li, E., Ramirez, A., Burkhardt, A. M., & Wang, S. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1681 · Cited by 73

Exploring lectin–glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses

da Silva, L. C. N., Mendonça, J. S. P., de Oliveira, W. F., Batista, K. L. R., Zagmignan, A., Viana, I. F. T., & Correia, M. T. D. S. (2020) · Glycobiology · doi:10.1093/glycob/cwaa099 · Cited by 65

A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2

Wang, M., Fu, T., Hao, J., Li, L., Tian, M., Jin, N., Ren, L., & Li, C. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.239 · Cited by 61

Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development

Zhu, Y., Li, J., & Pang, Z. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.06.001 · Cited by 59

Microarray patches enable the development of skin-targeted vaccines against COVID-19

Korkmaz, E., Balmert, S. C., Sumpter, T. L., Carey, C. D., Erdös, G., & Falo, L. D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.022 · Cited by 60

Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals

Mahajan, S., Kode, V., Bhojak, K., Coral, K., Lee, K. M., Manoharan, M., Ramesh, A., Sudheendra, H., Srivastava, A., Sathian, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92521-4 · Cited by 54

Pressure Injury Prevention in COVID-19 Patients With Acute Respiratory Distress Syndrome

Victoria Team, Lydia Team, Jones, A., Teede, H. J., & Weller, C. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.558696 · Cited by 53

A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Steinbuck, M. P., Seenappa, L. M., Jakubowski, A., McNeil, L. K., Haqq, C. M., & DeMuth, P. C. (2021) · Science Advances · doi:10.1126/sciadv.abe5819 · Cited by 49

Vaccine Hesitancy and Effects of COVID-19

Erkekoğlu, P., KÖSE, S. B. E., Balcı, A., & Yirün, A. (2020) · Journal of Literature Pharmacy Sciences · doi:10.5336/pharmsci.2020-76102 · Cited by 51

Knowledge, preventive behavior and risk perception regarding COVID-19: a self-reported study on college students

Elhadi, M., Msherghi, A. A. A., Alsoufi, A., Buzreg, A., Bouhuwaish, A. E. M., Khaled, A., Alhadi, A., Alameen, H., Biala, M. I., Elgherwi, A., et al. (2020) · Pan African Medical Journal · doi:10.11604/pamj.supp.2020.35.2.23586 · Cited by 46

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity

Fluckiger, A.-C., Ontsouka, B., Bozic, J., Diress, A., Ahmed, T., Berthoud, T. K., Tran, A., Duque, D., Liao, M., McCluskie, M. J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.034 · Cited by 43

Enhancing Robustness and Resilience of Multiplex Networks Against Node-Community Cascading Failures

Ma, L., Zhang, X., Li, J., Lin, Q., Gong, M., Coello, C. A. C., & Nandi, A. K. (2021) · IEEE Transactions on Systems Man and Cybernetics Systems · doi:10.1109/tsmc.2021.3073212 · Cited by 43

Potential Biases Arising From Epidemic Dynamics in Observational Seroprotection Studies

Kahn, R. J., Kennedy‐Shaffer, L., Grad, Y. H., Robins, J. M., & Lipsitch, M. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa188 · Cited by 40

Drug repurposing approach to combating coronavirus: Potential drugs and drug targets

Xu, J., Xue, Y., Zhou, R., Shi, P., Li, H., & Zhou, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21763 · Cited by 40

Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics

Kabra, R., & Singh, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165978 · Cited by 38

BCG vaccination induced protection from COVID-19

Mohapatra, P. R., Mishra, B., & Behera, B. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.08.004 · Cited by 38

COVID‐19: Emergence of Infectious Diseases, Nanotechnology Aspects, Challenges, and Future Perspectives

Gupta, A., Kumar, S., Kumar, R., Choudhary, A. K., Kumari, K., Singh, P., & Kumar, V. (2020) · ChemistrySelect · doi:10.1002/slct.202001709 · Cited by 35

ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC REVIEW

Dey, D., Ema, T. I., Biswas, P., Aktar, S., ISLAM, S., Rinik, U. R., Firoz, M., Ahmed, S. Z., Azad, S. A., Rahman, A., et al. (2021) · Frontiers of Agricultural Science and Engineering · doi:10.15302/j-fase-2021397 · Cited by 30

The Nigerian Pharmaceutical Supply Chain: Blockchain Adoption, Counterfeit Drugs and Successful Deployment of COVID-19 Vaccine in Nigeria

Labaran, M. J., & Hamma-Adama, M. (2021) · Journal of Scientific Research and Reports · doi:10.9734/jsrr/2021/v27i230356 · Cited by 28

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

Chakraborty, C., Sharma, A. R., Bhattacharya, M., Sharma, G., Saha, R. P., & Lee, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e5 · Cited by 26

Strategies for Immunomonitoring after Vaccination and during Infection

Adam, L., Rosenbaum, P., Bonduelle, O., & Combadière, B. (2021) · Vaccines · doi:10.3390/vaccines9040365 · Cited by 25

“Tomorrow Never Dies”: Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies

Laskar, P., Yallapu, M. M., & Chauhan, S. C. (2020) · Diseases · doi:10.3390/diseases8030030 · Cited by 29

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

Jackson-Thompson, B. M., Goguet, E., Laing, E. D., Olsen, C. H., Pollett, S. D., Hollis-Perry, M., Maiolatesi, S. E., Illinik, L., Ramsey, K. F., Reyes, A. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06233-1 · Cited by 23

COVID-19: respuesta inmune y perspectivas terapéuticas

Lozada-Requena, I., & Ponce, C. N. (2020) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2020.372.5490 · Cited by 32

Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death

Székely, L., Bozóky, B., Béndek, M., Ostad, M., Lavignasse, P., Haag, L., Wu, J., Xu, J., Gupta, S., Saccon, E., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07134 · Cited by 23

Generation of SARS-CoV‑2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases

Stamatakis, G. M., Samiotaki, M. K., Mpakali, A., Panayotou, G., & Stratikos, E. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00457 · Cited by 21

Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review

Zielińska, A., Eder, P., Karczewski, J., Szalata, M., Hryhorowicz, S., Wielgus, K., Szalata, M., Dobrowolska, A., Atanasov, A. G., Słomski, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147991 · Cited by 22

Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19

Coish, J. M., & MacNeil, A. J. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.06.006 · Cited by 18

Developing a reciprocating mechanism for the emergency implementation of a Mechanical Pulmonary Ventilator using an integrated CAD-MBD procedure

Pappalardo, C., Vece, A., Galdi, D., & Guida, D. (2022) · FME Transaction · doi:10.5937/fme2201238p · Cited by 18

Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2

Purbey, P. K., Roy, K., Gupta, S., & Paul, M. K. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.03.009 · Cited by 19

Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccinePreprint

Gauttier, V., Morello, A., Girault, I., Mary, C., Belarif, L., Desselle, A., Wilhelm, E., Bourquard, T., Pengam, S., Teppaz, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.14.240093 · Cited by 18

Characterizing clinical progression of COVID-19 among patients in Shenzhen, China: an observational cohort studyPreprint

Bi, Q., Hong, C., Meng, J., Wu, Z., Zhou, P., Ye, C., Sun, B., Kucirka, L. M., Azman, A. S., Wang, T., et al. (2020) · medRxiv · doi:10.1101/2020.04.22.20076190 · Cited by 15

Research ethics and public trust in vaccines: the case of COVID-19 challenge trials

Eyal, N. (2022) · Journal of Medical Ethics · doi:10.1136/medethics-2021-108086 · Cited by 15

Immunology and Population Health: Collaboration without Convergence

Fagan, M. B. (2023) · Philosophy of Science · doi:10.1017/psa.2023.21 · Cited by 15

Nanomedicinal Delivery of Stimulator Of Interferon Genes Agonists: Recent Advances in Virus Vaccination

Chattopadhyay, S., & Hu, C. J. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0269 · Cited by 15

Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 16

Potential of live pathogen vaccines for defeating the COVID‐19 pandemic: History and mechanism

Chen, J., & Chen, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25920 · Cited by 14

The perplexing question of trained immunity vs adaptive memory in COVID‐19

Kerboua, K. E. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26083 · Cited by 14

BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine?

Kamat, S., & Kumari, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01050 · Cited by 14

Immunité adaptative contre le virus SARS-CoV-2

Combadière, B. (2020) · médecine/sciences · doi:10.1051/medsci/2020168 · Cited by 14

Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses

Dawson, E. D., Kuck, L. R., Blair, R. H., Taylor, A. W., Toth, E., Knight, V., & Rowlen, K. L. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114111 · Cited by 14

COVID‐19 vaccines and nanomedicine

Shapiro, R. S. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15673 · Cited by 14

The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2

Morris, K. V. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.005 · Cited by 14

COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus

Tavakol, S., Alavijeh, M. S., & Seifalian, A. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201023143956 · Cited by 13

Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?

Helle, K. B., Sadiku, A., Zelleke, G. M., Bouba, A., Ibrahim, T. B., Obama, H. C. J. T., Appiah, V., Ngwa, G. A., Teboh-Ewungkem, M. I., & Schneider, K. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253758 · Cited by 12

COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact

Maxwell, D. N., Sanders, K. C., Sabot, O. J., Hachem, A. A., Llanos‐Cuentas, A., Olotu, A., Gosling, R. D., Cutrell, J. B., & Hsiang, M. S. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0200 · Cited by 14

Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms

Bayat, M., Asemani, Y., & Najafi, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107679 · Cited by 15

A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2

Sarkar, A., Paul, S., Singh, C., Chowdhury, N., Nag, P., Das, S., Kumar, S., Sharma, A., Das, D. K., Dutta, D., et al. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198768 · Cited by 11

The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review.

Kyriakopoulos, A. M., Papaefthymiou, A., Georgilas, N., Doulberis, M., & Kountouras, J. (2020) · Archives of Academic Emergency Medicine · Cited by 12

COVID-19 and SARS-CoV-2: Everything we know so far – A comprehensive review

Naz, S., Zahoor, M., Sahibzada, M. U. K., Ullah, R., & Alqahtani, A. S. (2021) · Open Chemistry · doi:10.1515/chem-2021-0049 · Cited by 14

Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs

Maurya, R., Shamim, U., Mishra, P., Swaminathan, A., Raina, A., Tarai, B., Budhiraja, S., & Pandey, R. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04292-22 · Cited by 11

Engineered human mesenchymal stem cells as new vaccine platform for COVID-19Preprint

Liu, J., Jiao, H., & Yin, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.163030 · Cited by 11

Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment

White, I. A., Tamot, N., Doddareddy, R., Ho, J., Jiao, Q., Harvilla, P. B., Yang, T., Geist, B. J., Borrok, M. J., Truppo, M. D., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1987180 · Cited by 11

Topics in Antivax and Provax Discourse: Yearlong Synoptic Study of COVID-19 Vaccine Tweets

Zaidi, Z., Ye, M., Samon, F., Jama, A., Gopalakrishnan, B., Gu, C., Karunasekera, S. A., Evans, J., & Kashima, Y. (2023) · Journal of Medical Internet Research · doi:10.2196/45069 · Cited by 11

The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview

Brooks, N. A., Narayan, V. M., Hegarty, P. K., Zafirakis, H., Han, X., & Kamat, A. M. (2020) · BJUI Compass · doi:10.1002/bco2.21 · Cited by 9

Vaccine-enhanced disease: case studies and ethical implications for research and public health

Jamrozik, E., Heriot, G., Bull, S., Parker, M. J., & (GLIDE), O.-J. H. G. I. D. E. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16849.1 · Cited by 10

Determinants and Willingness to Pay for Purchasing Mask against COVID-19: A Protection Motivation Theory Perspective

Ding, Q., Lin, S., & Wang, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074268 · Cited by 10

COVID-19 in Light of Seasonal Respiratory Infections

Kiseleva, I., Grigorieva, E., Larionova, N. V., Farroukh, M. A., & Георгиевна, Р. Л. (2020) · Biology · doi:10.3390/biology9090240 · Cited by 10

Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies

Steuwer, B., Jamrozik, E., & Eyal, N. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.038 · Cited by 9

An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2

Xie, T., He, Z., Liang, C., Dong, H.-N., Zhou, J., Fan, S.-J., & Guo, X. (2021) · European journal of medical research · doi:10.1186/s40001-021-00609-4 · Cited by 9

A review of COVID‐19 vaccines and major considerations for diabetic patients

Soltani, S., Zandi, M., Aghbash, P. S., Rezaei, M., Mohammadzadeh, N., Afsharifar, A., & Poortahmasebi, V. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2076 · Cited by 8

Attitude and Acceptance towards COVID-19 Booster Doses among Literacy Advantaged Population in Pakistan: A Cross-Sectional Study

Ahmad, M., Sattar, A., Aroosa, S., Majeed, A., Rasheed, M. A., Ahmad, W., Iqbal, A., Omer, M. O., Beg, B. M., & Mushtaq, R. M. Z. (2023) · Vaccines · doi:10.3390/vaccines11071238 · Cited by 8

PNAS and the pandemic

Berenbaum, M. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006488117 · Cited by 8

Phytochemicals as Potential Curative Agents against Viral Infection: A Review

Kumar, A., Singh, A. K., & Tripathi, G. (2020) · Current Organic Chemistry · doi:10.2174/138527282499920091009352 · Cited by 7

Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19

Poteryaev, D. A., Авгатович, Х. Р., Efimov, G. A., & Shuster, А. М. (2020) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2020-20-3-146-158 · Cited by 7

Profile of SARS-CoV-2

Heinz, F. X., & Stiasny, K. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01763-1 · Cited by 8

An Account of Immune Senescence in the Clinical Pathophysiology of COVID-19 Infection in Aging

Jain, S., Abrham, E., Khan, M., & Mathur, R. (2021) · Aging and Disease · doi:10.14336/ad.2020.1019 · Cited by 7

SARS-CoV-2-induced host metabolic reprogram (HMR): nutritional interventions for global management of COVID-19 and post-acute sequelae of COVID-19 (PASC)

Naidu, A. S., Shahidi, F., Wang, C., Sato, K., Wirakartakusumah, A., Aworh, O. C., & Clemens, R. (2022) · Journal of Food Bioactives · doi:10.31665/jfb.2022.18306 · Cited by 7

Comparative seasonalities of influenza A, B and ‘common cold’ coronaviruses – setting the scene for SARS-CoV-2 infections and possible unexpected host immune interactions

Liu, Y., Lam, T. T., Lai, F. Y. L., Krajden, M., Drews, S. J., Hatchette, T. F., Fraaij, P. L. A., van Kampen, J. J. A., Badarch, D., Nymadawa, P., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.032 · Cited by 7

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests

Eyal, N., Gerhard, T., & Strom, B. L. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.056 · Cited by 6

Pandemic number five – Latest insights into the COVID-19 crisis

Häfner, S. J. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.08.008 · Cited by 6

Current Status of COVID‐19 (Pre)Clinical Vaccine Development

Ye, T., Zhong, Z., García‐Sastre, A., Schotsaert, M., & Geest, B. G. D. (2020) · Angewandte Chemie · doi:10.1002/ange.202008319 · Cited by 6

Leveraging Nanotechnology for Addressing COVID-19: Revealing Antiviral Approaches and Hurdles

Mostafavi, M., & Shabani, M. (2024) · World Journal of Nano Science and Engineering · doi:10.4236/wjnse.2024.141001 · Cited by 5

Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges

Abdullahi, I. N., Emeribe, A. U., Adekola, H. A., Abubakar, S. D., Dangana, A., Shuwa, H. A., Nwoba, S. T., Mustapha, J. O., Haruna, M., Olowookere, A. K., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1812313 · Cited by 5

COVID-19 vaccine design: the Janus face of immune enhancement

Hotez, P. J., Corry, D. B., & Bottazzi, M. E. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0323-4 · Cited by 168

Prospects for a safe COVID-19 vaccine

Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

de Alwis, R., Chen, S., Gan, E. S., & Ooi, E. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102768 · Cited by 132

Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety

Kostoff, R. N., Kanduc, D., Porter, A. L., Shoenfeld, Y., Călina, D. C., Briggs, M. B., Spandidos, D. A., & Tsatsakis, A. M. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.10.016 · Cited by 61

Coronavirus vaccine developers wary of errant antibodies

Garber, K. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00016-w · Cited by 11